Associated tags: CLX, Pain management, Exosome, Central nervous system, Research, Epilepsy, CNS, CBD, Science, Patient, LPT, Cannabinoid, Medication, Quality of life, CSE, FSE, Pharmaceutical industry, FDA, AB
Locations: CANADA, ALBERTA, ISRAEL, UNITED STATES OF AMERICA, RAMOT, JERUSALEM, LITHUANIA, BELGIUM, SLOVAKIA, US, FINLAND, AUSTRIA, ESTONIA, LATVIA, ONTARIO, UNITED STATES, NEW YORK, CALGARY, CA, BRITISH COLUMBIA
Pain,
Euthanasia,
Animal,
Inflammation,
Laminitis,
AB,
Female,
Disease,
Human,
Therapy,
Amputation,
Patient,
Caregiver,
Abscess,
Horse Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb.
Key Points:
- Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb.
- As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection.
- "Thanks to our innovative liposomal-CBD injection, we are thrilled to have brought relief to Miri, eliminating the need for euthanasia," commented Iris Bincovich, CEO of Innocan.
- "Laminitis is a crippling condition well familiar and common in horses," said Prof Chezy Barenholz, the Chief Scientific Officer of Innocan.
FDA,
Food,
Drug overdose,
Animal,
AB,
Research,
IND,
Letter,
Human,
Investigational New Drug,
Therapy,
Pain management,
LPT,
Chronic pain,
Pharmaceutical industry HERZLIYA, Israel and CALGARY, AB, April 22, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
Key Points:
- Innocan's therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it's LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions.
- Innocan's Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans.
- This is a key milestone for Innocan and marks our first step towards the FDA's recognition of our technology.
- We look forward to working under FDA guidance, with the goal of completing the review process as quickly and efficiently as possible.
Sky Global,
LPT,
Gross income,
Beauty,
Patient,
Operating cost,
CBD,
Bank statement,
OTC,
Chronic pain,
FDA,
Pharmaceutical industry This significant increase in revenue was primarily due to the robust sales performance of Innocan's subsidiary, BI Sky Global Ltd.
Key Points:
- This significant increase in revenue was primarily due to the robust sales performance of Innocan's subsidiary, BI Sky Global Ltd.
- Gross Profit increased 568% year-over-year to US$12.0 million for the year ended December 31, 2023, compared to US$2.1 million for 2022.
- Iris Bincovich, the CEO of Innocan commented: "We are very pleased with our performance in 2023, closing the year with a strong fourth quarter.
- Roni Kamhi, CEO BI Sky Global and COO of Innocan Pharma commented: "Our consumer wellness products are trusted by millions of customers.
Al-Quds,
Chemistry,
AB,
Research,
Hebrew University of Jerusalem,
CBD,
CDC,
Marketing,
FDA,
Food,
Pharmaceutical industry To date, Innocan has focused on the development and characterization of LPT-CBD to achieve its long-term release and effectiveness.
Key Points:
- To date, Innocan has focused on the development and characterization of LPT-CBD to achieve its long-term release and effectiveness.
- Innocan is now initiating the following essential development steps that are expected to move LPT-CBD to a pharmaceutical-grade product that must be qualified by the FDA for both the clinical and marketing phases:
The definition of the physical and chemical specifications of LPT-CBD as required from a pharmaceutical product.
- The expansion of LPT-CBD production from small laboratory quantities to large quantities in pharmaceutical grade.
- Iris Bincovich Innocan Pharma's CEO stated: "This is a major step in the development of LPT-CBD, moving it from a research laboratory-level drug to a pharmaceutical-grade product that must be qualified by the FDA for both the clinical and marketing phases."
HERZLIYA, Israel and CALGARY, Alberta, March 14, 2024 /PRNewswire/ -- Innocan Pharma Corporation (the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the "Offering") of units of the Company (the "Units"), pursuant to which the Company issued 7,952,840 Units at a price of $0.25 per Unit (the "Offering Price") for aggregate gross proceeds of $1,988,210.
Key Points:
- Each Unit is comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant").
- This successful financing is another illustration of the confidence and trust that the investment community has in the future milestones of Innocan.
- The Company intends to use the proceeds from the Offering for working capital and general corporate purposes.
- Each RSU entitles the recipient to receive one common share of the Company (a "Common Share") on vesting.
Regeneration,
Regulation,
LPT,
Person,
Blood,
Pathology,
News,
Cannabidiol,
Animal,
Dog,
Schizophrenia,
Sheep,
Stroke,
Goat,
Indian stock exchange,
Unit,
Pharmacokinetics,
Rabbit,
DSM-IV codes,
Spectrum,
B.B.B,
Mouse,
Brain,
Medical imaging HERZLIYA, Israel and CALGARY, Alberta, March 5, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the following:
Key Points:
- In the Company's latest study, CBD was found to be in the brains of both mice and rabbits weeks after LPT-CBD was subcutaneously injected to them.
- These results show a strong correlation between the prolonged blood exposure of CBD and its brain distribution.
- Sufficient exposure of CBD in the brain is the hallmark of CBD therapy associated with various neurological conditions.
- The fact that LPT-CBD successively delivers CBD to the brain in a long-lasting manner opens a big venue for the treatment of various neurological disorders.
Retrieved on:
Monday, February 26, 2024
AB,
LPT,
CMAX,
Blood,
Animal,
Dog,
Sheep,
Goat,
Tmax,
Pharmacokinetics,
Rabbit,
Half-life,
Mouse The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream.
Key Points:
- The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream.
- In the Company's latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.
- The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform.
- In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days.
Retrieved on:
Tuesday, February 20, 2024
HERZLIYA, Israel and CALGARY, Alberta, Feb. 20, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to announce that CEO Iris Bincovich will be a speaker at the White Label World Expo in London on February 27th and 28th.
Key Points:
- HERZLIYA, Israel and CALGARY, Alberta, Feb. 20, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to announce that CEO Iris Bincovich will be a speaker at the White Label World Expo in London on February 27th and 28th.
- The White Label World Expo is the world's largest event for the white label industry, where sellers, suppliers and buyers converge to network, learn, and explore opportunities.
- https://www.whitelabelexpo.co.uk/speakers/
Innocan's consumer wellness portfolio, featuring topicals and cosmetics, backed by proven efficacy and patent application demonstrate our dedication to health and wellness, providing a solution for the growing consumer demand for effective wellness products.
- Innocan's participation at the White Label World Expo supports the Company's diversified market access strategy that includes joint ventures, online marketplaces, brick-and-mortar distribution, and white label partnerships to leverage existing wellness brand consumer bases and maximize market reach.
Retrieved on:
Tuesday, December 12, 2023
Drug development,
FSE,
Emeritus,
Research,
DABT,
Chronic pain,
CSE,
Entrepreneurship,
Veterans Health Administration,
CBD,
Therapy,
LPT,
Toxicology,
Book,
Patient,
Analgesic,
FDA,
Biology,
Pharmacology,
Caregiver,
MD,
Drug discovery,
Abstract,
University,
Thermodynamics,
The Co Founder,
Doctor of Philosophy,
Commendation,
Publication,
Partnership,
Pharmaceutical industry,
Pharmacy The team is comprised of accomplished drug development and drug approval experts, with specific a experience in pharmacology, toxicology, clinical trials, and successful interaction with the FDA.
Key Points:
- The team is comprised of accomplished drug development and drug approval experts, with specific a experience in pharmacology, toxicology, clinical trials, and successful interaction with the FDA.
- Dr. Robert B. Raffa, PhD, is Adjunct Professor at the University of Arizona College of Pharmacy and Professor Emeritus at Temple University School of Pharmacy.
- Innocan CEO, Iris Bincovich, stated: "At Innocan, we continue to develop our liposomal CBD platform to play a role in effectively combating various diseases in the future.
- We are excited to work with such leading experts to help Innocan Pharma achieve our gools and move the company forward with the FDA."
Retrieved on:
Wednesday, November 29, 2023
US$4.083M Revenues for Q3 2023 compared to US$749,000 for Q3 2022, representing an increase of 445%
Key Points:
- US$4.083M Revenues for Q3 2023 compared to US$749,000 for Q3 2022, representing an increase of 445%
US$3.664M Gross Profit for Q3 2023 compared to USD 715,000 for Q3 2022, representing an increase of approximately 412%
HERZLIYA, Israel and CALGARY, Alberta, Nov. 29, 2023 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary intellectual property portfolio, is pleased to announce its financial results for the three and nine months period ended September 30, 2023.
- "We are thrilled with the significant growth we achieved in the third quarter," says Iris Bincovich, CEO of Innocan.
- Financial highlights for the third quarter of 2023:
Revenue: The Company posted US$4.083M in revenue for the three months ended September 30, 2023, marking an increase of US$3.334M compared to the three months ended September 30, 2022.
- Gross Profit: For the three months ended September 30, 2023, the Company reported a gross profit of US$3.664M, compared to US$715,000 for the three months ended September 30, 2022, representing an increase of US$2.949M.
